Last reviewed · How we verify
other intravenous chemotherapy drugs
other intravenous chemotherapy drugs is a Small molecule drug developed by Centre Georges Francois Leclerc. It is currently in Phase 2 development.
At a glance
| Generic name | other intravenous chemotherapy drugs |
|---|---|
| Sponsor | Centre Georges Francois Leclerc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of TAK-505 in Adults With Solid Tumors (PHASE1, PHASE2)
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (PHASE1, PHASE2)
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) (PHASE3)
- A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer (PHASE1, PHASE2)
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) (PHASE1, PHASE2)
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (PHASE3)
- Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) (PHASE2)
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- other intravenous chemotherapy drugs CI brief — competitive landscape report
- other intravenous chemotherapy drugs updates RSS · CI watch RSS
- Centre Georges Francois Leclerc portfolio CI
Frequently asked questions about other intravenous chemotherapy drugs
What is other intravenous chemotherapy drugs?
other intravenous chemotherapy drugs is a Small molecule drug developed by Centre Georges Francois Leclerc.
Who makes other intravenous chemotherapy drugs?
other intravenous chemotherapy drugs is developed by Centre Georges Francois Leclerc (see full Centre Georges Francois Leclerc pipeline at /company/centre-georges-francois-leclerc).
What development phase is other intravenous chemotherapy drugs in?
other intravenous chemotherapy drugs is in Phase 2.